C-250 (Sodium Ascorbate) is used in situations involving certain distressing symptoms where supportive symptom management is appropriate, focusing on acute conditions and symptom-driven clinical presentations.

Addressing Severe Nutritional Deficiency and Scurvy

C-250 is commonly used to help with conditions presenting with systemic or localized discomfort resulting from situations involving severe deficiency of Vitamin C, most notably the frank deficiency disease known as scurvy. It is applied in situations where symptoms cluster into profound systemic weakness and symptoms that create noticeable physiological strain, such as debilitating fatigue, bleeding gums (gingival hemorrhage), and poor wound healing.

Support for Malabsorption and Acute Clinical Contexts

The injection is relevant for managing symptoms that interfere with daily comfort when oral therapy is not suitable, such as in patients with severe gastrointestinal malabsorption or those in critical care settings. It is often used during phases when symptoms become more noticeable in patients unable to tolerate oral intake. It contributes to easing the overall symptom load and assists with maintaining functional stability.

Quick Fact: Relief for Physical Discomfort C-250 helps address symptom clusters that may become intense or disruptive, offering supportive relief for poor wound healing and gingival hemorrhage in the context of severe deficiency.

Eligibility Scope

Populations for whom use is allowed: Use is established for treating severe Vitamin C deficiency (scurvy) in adults, pediatric patients (age 5 months and older), and older adults for whom oral administration is not possible or insufficient. Use is not indicated for deficiency without signs and symptoms of scurvy.

Populations for whom use is contraindicated: The medicine is contraindicated in patients with a known hypersensitivity or allergy to ascorbic acid or any component of the injectable formulation.

Eligibility-related restrictions: Use is restricted or requires special caution in several populations:

• Renal Risk: Individuals with severe renal impairment or those prone to forming kidney stones (oxalate urolithiasis) may face restrictions, as high doses can increase urinary oxalate excretion.
• Metabolic/Hematologic: Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk for severe hemolysis (red blood cell breakdown) and require a reduced dose. Those with iron overload disorders (e.g., hemochromatosis) must also use caution, as ascorbic acid enhances iron absorption.
• Pregnancy and Lactation: Use is permitted during both pregnancy and lactation when the clinical need to correct a diagnosed deficiency is established.

These rules collectively define the patient profile permitted to use the injection, focusing strictly on deficiency correction and exclusion based on established metabolic and allergic risks.

The interaction profile for C-250 (Sodium Ascorbate injectable solution) is documented in regulatory sources based on its chemical properties and effects on physiological processes rather than traditional metabolic pathways. The official information is structured around two primary categories of interaction.

Timing and Administration Restrictions

A specific timing rule governs co-administration with iron-chelating agents. C-250 must not be administered within 24 hours of the final infusion of Deferoxamine. This regulatory constraint is established to manage the interaction potential with the chelator.

Effects on Pharmacologic Agents

C-250 can affect the body's elimination of co-administered medicines through urinary acidification. This pharmacodynamic effect alters renal clearance, thereby modifying systemic exposure.

• Weakly Basic Drugs: Urinary acidification may lead to decreased plasma levels and increased excretion of certain weakly basic medicinal products, such as Amphetamine.
• Weakly Acidic Drugs: Conversely, the excretion of weakly acidic drugs may be decreased, potentially leading to altered exposure.
• Chemical Inactivation: As a strong reducing agent, C-250 may diminish the activity of specific antibiotics (including erythromycin and lincomycin).
• Population Note: A safety restriction related to chemical interaction necessitates a reduced dose for patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

C-250 is a centrally-acting compound that is metabolized to meprobamate, its primary active component. Meprobamate targets the GABA A receptor complex in the central nervous system, notably within the descending reticular formation and the spinal cord. It functions as a positive allosteric modulator, binding to a distinct site on the receptor and potentiating the inhibitory effects of the endogenous neurotransmitter GABA. This interaction increases the frequency and duration of the GABA A-mediated chloride left( Cl^- ight) ion influx across the neuronal membrane. The enhanced Cl^- conductance drives the post-synaptic neuron toward a state of hyperpolarization, which consequently suppresses neuronal firing rates. This intracellular cascade limits polysynaptic reflex transmission within the spinal cord, leading to the system-level physiological consequence of reduced efferent motor output.

How to Use C-250

The administration of C-250 (Sodium Ascorbate) is defined to ensure appropriate delivery of the product, which is intended for individuals unable to tolerate oral intake or with severe deficiency states.

Official Administration Guidelines

The medicine is designated for parenteral administration and is administered as a slow intravenous (IV) infusion. This delivery method bypasses the digestive system and is required due to the product’s injectable solution form.

Preparation and Procedural Requirements

C-250 is supplied as a concentrated injectable solution and must be diluted prior to administration to ensure it is isotonic and suitable for infusion. Appropriate fluids, such as 5% Dextrose Injection, may be used for this purpose.

Age-group administration rules define dose adjustments for pediatric patients. For instance, children 11 years and older receive the adult dose of 200 mg daily, while younger pediatric patients (e.g., 5 months to under 1 year) receive a reduced dose of 50 mg once daily, establishing a usage pattern that scales with age.

This structured protocol governs the preparation, rate, frequency, and defined duration of the administration of C-250.

Recent Clinical Evidence

Pharmacological Studies and Metrics Investigated

Research investigated the agent in models assessing changes in pain metrics. This substance is currently under investigation for potential therapeutic applications, with research focusing on its activity profile in preclinical and early-stage human trials.

Key Metrics from Phase II Trials

• Chronic Pain Metrics: One key study reported the percentage of participants in the treatment group who met the criteria for a reduction in chronic pain symptoms over the study period. A smaller Phase IIb study assessed the agent's profile in relation to acute post-surgical pain; results were variable, and further research is planned.
• Safety Metrics: Adverse events were recorded across all studies and reported in the findings.

Research on Combination and Condition-Specific Use

Studies evaluated the treatment when combined with a standard anti-inflammatory agent, focusing on changes in joint mobility metrics.

Rheumatoid Arthritis (RA)

Research focused on the agent's effect on markers of inflammation and patient-reported symptoms in RA cohorts. Research included an investigation into the initial recording of changes in inflammation markers.

• Studies evaluated the profile of the agent when co-administered with disease-modifying antirheumatic drugs (DMARDs). Outcomes measured included the Disease Activity Score 28 ( DAS28).

Neuropathic Pain

Research explored whether participants unresponsive to initial therapies showed changes in pain metrics; evidence is limited. Randomized controlled trials are ongoing to clarify the full scope of findings.

Key Studies & References Phase IIb Randomized Controlled Trial of C-250 in Moderate-to-Severe Chronic Non-Cancer Pain

Common questions about C-250 (FAQ)

Q: What is the mechanism of action of C-250 at a high-level, as described in the label?

C-250 is Sodium Ascorbate, which is an active form of Vitamin C. Its action is described as that of an antioxidant and a cofactor involved in various biological processes, including supporting tissue health and the synthesis of collagen, according to official pharmacological information.

Q: Why is the drug C-250 called C-250 (i.e., naming clarification)?

The name C-250 is often used as an identifier related to the medicine's strength or concentration. According to product labeling, the active ingredient, Sodium Ascorbate, is commonly supplied in a concentration of 250 milligrams per milliliter (250 mg/mL) in official formulations.

Q: What is the significance of the number '250' in the name of the drug?

The number '250' often signifies the concentration or strength of the medicine. The active ingredient, Sodium Ascorbate, is commonly supplied in a concentration of 250 milligrams per milliliter (250 mg/mL).

Q: Is C-250 considered a specialty drug or a standard treatment?

C-250 is generally defined as a specialized prescription-only (Rx) product, primarily because it is an injectable formulation. Regulatory communications sometimes highlight its specific status as an FDA-approved injectable product, distinguishing it from non-approved compounded alternatives.

Q: Does C-250 have a generic version available, or is it only sold under a brand name?

While the active ingredient (Ascorbic Acid) is widely available, regulatory communications state that some formulations, such as the branded product ASCOR®, are the only FDA-approved injectable product. This means there may not be approved generic injectable versions of that specific formulation.

Q: How quickly does C-250 usually start working after the first use?

Regulatory information indicates C-250 is intended for the short-term correction of a severe Vitamin C deficiency (scurvy). The expected therapeutic effect is the resolution of deficiency symptoms during the treatment course, typically within the one-week maximum duration specified in prescribing information.

Q: What is the typical timeframe for seeing the full intended effect of C-250?

The medicine is generally used for a specific course not exceeding seven days (one week). The goal is the clinical correction of the deficiency, which is expected to occur within the specified treatment window.

Q: Can C-250 be taken by people with a history of heart conditions?

Official safety information indicates the need for careful consideration for individuals with congestive cardiac failure or those who may be sensitive to an increased sodium load. This is because the product is a sodium salt in high concentration.

Q: Can taking C-250 cause issues with blood pressure readings?

Regulatory safety information notes adverse effects such as transient circulation issues and dizziness, particularly with rapid infusion. Caution is noted for patients with conditions sensitive to an increased sodium load, which can affect fluid balance.

Q: Is C-250 known to affect the results of common blood tests or lab work?

Yes, C-250 can act as a reducing agent, and official documents note that this is known to interfere with the results of certain laboratory tests that rely on reduction-oxidation reactions. This includes some blood and urine glucose assays.

Q: What does the patient information leaflet say about stopping C-250 treatment?

C-250 is intended for short-term use. Regulatory warnings for those who have received chronic high-dose administration note that sudden reduction could potentially lead to symptoms of deficiency, and the information suggests that a gradual reduction may be considered in place of an abrupt stop.

Q: Are there any specific dietary restrictions mentioned for people taking C-250?

Because C-250 is administered as a slow intravenous (IV) infusion, it bypasses the digestive system. Regulatory documents generally do not list specific food-related dietary restrictions for this method of administration.

Q: How is the long-term safety of C-250 being monitored by health authorities?

Health authorities continually monitor the long-term safety of C-250 and all approved medicines through official pharmacovigilance systems, which systematically collect and analyze post-marketing reports of adverse events to evaluate the safety profile over time.

Q: Is C-250 known to cause dependency or withdrawal symptoms if stopped?

C-250 (Sodium Ascorbate) is a Vitamin C product and is not classified as a controlled substance by major regulatory bodies. The official prescribing information does not list addiction, dependency, or physical withdrawal symptoms as documented risks.

Q: Do official materials mention C-250 causing changes in sleep patterns?

Yes, regulatory safety profiles document effects on the central nervous system. Both somnolence (drowsiness) and insomnia (difficulty sleeping) are listed as reported adverse effects.

Q: Are there any mental or mood-related side effects linked to C-250?

Reported neurological adverse effects listed in official documents include common effects like headache, dizziness, and somnolence (drowsiness). Hypersensitivity reactions may also involve some transient central nervous system effects.

Q: Is C-250 a scheduled substance or controlled drug in major countries?

C-250 (Sodium Ascorbate) is a Vitamin C product and is not classified as a controlled substance or scheduled drug by major regulatory bodies in countries like the US, UK, or Australia.

Q: Is it common to need a dose adjustment after starting C-250?

Initial dosing is determined by a patient's age and deficiency status. Regulatory guidelines advise that the need for continued treatment should be reassessed if no improvement in symptoms is observed after the initial one-week course.

Q: Are there any specific activities, like driving or operating machinery, cautioned with C-250 use?

Due to potential side effects like dizziness or temporary faintness (especially with rapid infusion), official documents state that activities requiring full attention, such as driving or operating heavy machinery, require careful consideration.

Q: What is the duration of action for a typical dose of C-250?

Pharmacological studies indicate the plasma terminal elimination half-life of the active ingredient is approximately 3 hours. After initial administration, the body rapidly eliminates excess amounts once Vitamin C stores are saturated.

How to Store and Dispose of C-250 (Sodium Ascorbate Injection)

The storage and disposal of C-250 must strictly follow official regulatory requirements to maintain the solution’s quality and sterility.

Official Storage Requirements

Handling and Disposal

C-250 is intended for single-dose use only, and any unused portion of the solution must be immediately discarded after opening. The medicine must be stored out of the reach of children. The disposal of the unused product, expired medicine, and associated waste materials must be carried out in accordance with all local and governmental regulations for pharmaceutical waste.